COVID-19 vaccine but delaying a second dose among people younger than 65 could lead to fewer people dying of the disease, but only if certain conditions are met, a predictive modeling study showed.As the coronavirus pandemic continues, there is debate over whether to extend the gap between doses to give as many people as possible some protection, or stick to the intervals designated in clinical trials.For example, Pfizer has said there is no clinical evidence to support Britain’s decision to extend the gap between doses of its vaccine to 12 weeks, but data from the rollout in England shows protection against death of around 80 per cent from one dose, with a 70 per cent decline in infections.The U.S.